drugset / Trial / NCT03734601

Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation

NCT03734601

Phase 2 Completed 22 enrolled Stanford University
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate whether addition of a low dose of total body irradiation (TBI) to a standard preparation for transplant \[total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG)\] conditioning will help to augment donor chimerism without reducing tolerability of this regimen or increasing the risk of graft-vs-host disease (GVHD)

Timeline

Start
2018-11-05
Primary completion
2019-12-26
Completion
2020-11-17

Drugs

EvaluationDrugModalityDoseRoute
Background ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic 1.5 mg/kg Intravenous
Background Mycophenolate Mofetil Small molecule 15 mg/kg Oral
Background Tacrolimus Small molecule 0.05 mg/kg Oral